We’re teaming up with Bright Minds Biosciences again to evaluate the #EEG data in the Company's BREAKTHROUGH study evaluating the safety, tolerability and efficacy of BMB-101 using Firefly’s FDA-cleared #AI BNA™ platform. Learn more: feeds.issuerdirect.com/news-release.h… #BrainHealth $AIFF $DRUG

BNA™ leverages #AI and #MachineLearning to analyze #EEG data and compare it to an extensive FDA-cleared, normative age-matched database to identify deviations and patterns. Ready to harness the power of BNA™? Contact us: fireflyneuro.com/contact

What if clinicians and neurologists could objectively measure #BrainHealth? Utilizing #EEG technology, advanced #AI and an extensive proprietary EEG database, BNA™ provides comprehensive, objective, data-driven brain health evaluations. Learn more: fireflyneuro.com $AIFF

BNA™ equips clinicians & #neurologists with comprehensive insights into each patient's brain to identify underlying neurological issues & tailor treatment plans to each patient’s neurological profile. Discover how BNA™ can transform your practice: fireflyneuro.com/our-technology/ $AIFF

By harnessing the power of #AI, advanced signal processing and big data with cloud computing, BNA™ leverages the latest technologies to revolutionize #BrainHealth. Ready to learn more about BNA™ and what it can do for your practice? Contact us: fireflyneuro.com/contact/ $AIFF

#Stress can impact #memory and #cognition and increase the risk of developing various neurological conditions. With our BNA™ technology, healthcare professionals can objectively assess cognitive function and track the impact of stress over time: fireflyneuro.com/our-technology/ $AIFF

Our management will participate in the CEM Management Conference (CEM) in Aventura, Florida from November 22 through 24. If you’d like to schedule a one-on-one #investor meeting with us, please email us at [email protected] or contact your representatives at CEM. $AIFF

According to Epilepsy Foundation of America, 1 in 3 #epilepsy patients experience drug resistance. Bright Minds Biosciences is leveraging our BNA™ technology to evaluate data from the Phase 2 clinical study of its lead compound developed to treat refractory epilepsy: feeds.issuerdirect.com/news-release.h… $AIFF $DRUG

Our FDA-cleared BNA™ platform is driving the future of neurological assessments by leveraging Event Related Potentials, quantitative spectral #EEG, behavioral results & advanced #AI analysis to unlock powerful insights. Learn more: fireflyneuro.com $AIFF #BrainHealth

We're harnessing the power of #AI & next generation neurological insights to revolutionize brain #healthcare. BNA™’s AI-based #EEG analysis encompasses ERP, quantitative spectral EEG & behavioral results in one FDA-cleared tool. Learn more: fireflyneuro.com/healthcare-pro… $AIFF

With our innovative, #AI-driven BNA™ platform, clinicians & neurologists can track disease progression over time to evaluate treatment efficacy, provide personalized care & promote better outcomes. Ready to harness the power of BNA™? Contact us: fireflyneuro.com/contact/ $AIFF

Our CEO, Jon Olsen, sat down with Authority Magazine to discuss Firefly’s work to disrupt the standard of neurological care and what’s ahead for the company in 2025. Read more here: medium.com/authority-maga… #AI #Healthcare #Innovation $AIFF

BNA™’s advanced #AI analysis unlocks a deep understanding of #brain activity to help clinicians and neurologists better understand the severity and progression of each patient’s condition. Learn more about BNA™ and its revolutionary potential: fireflyneuro.com/our-technology/ $AIFF

A simple recording can unlock next-generation #BrainHealth insights with Firefly’s BNA™ technology. Discover how our patented #AI algorithms extract personalized cognitive measures to provide a detailed assessment of #brain activity: fireflyneuro.com/healthcare-pro… $AIFF

Firefly's Laura Szklarski is joining Zeto this weekend at #AES2024 at the Los Angeles Convention Center. Stop by Zeto Booth #1219 on December 7 or 8 from 1 – 2 pm to hear how our #AI-driven BNA™ technology can advance epilepsy care. See you there! American Epilepsy Society $AIFF

Firefly’s FDA-cleared BNA™ platform is powered by advanced #AI technology that transforms vast #EEG data into critical insights to continuously refine clinicians’ understanding and treatment of neurological conditions. Learn more: fireflyneuro.com $AIFF

Personalized medicine is set to continue driving #healthcare advancements in 2025. With new, #AI-driven tools, like our BNA™ platform, healthcare providers can unlock powerful insights and tailor care to each patient. forbes.com/sites/bernardm… $AIFF

In 2024, Firefly has continued to advance our AI-driven BNA platform and formed partnerships integrating our powerful technology into clinical research and neurological care. Read more about these collaborations on our website: investors.fireflyneuro.com/press-releases $AIFF $DRUG